GlassScriptPhysician profile
Alex S Lapasaran
NPI 1134183494
$50,366.58
in general payments reported to CMS, 2019-2025
22 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,733 · 2022: $5,265 · 2023: $9,265 · 2024: $15K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $5,248 · Travel and Lodging: $4,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,470.00 |
| Food and Beverage | $5,247.69 |
| Travel and Lodging | $4,650.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $47,971.98 | 2021-2025 | Epclusa, Vemlidy, Livdelzi |
| Genzyme Corporation | $488.94 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.21 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $213.98 | 2021-2024 | |
| Madrigal Pharmaceuticals | $177.67 | 2025 | Rezdiffra |
| Novo Nordisk INC | $155.57 | 2025 | Wegovy |
| Boston Scientific Corporation | $147.39 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Regeneron Healthcare Solutions, INC. | $122.42 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $105.41 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $102.53 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $101.55 | 2024-2025 | Eohilia, Entyvio |
| Intercept Pharmaceuticals, INC. | $80.36 | 2022-2024 | Ocaliva |
| Lucid Diagnostics INC. | $76.66 | 2022 | |
| Redhill Biopharma INC. | $71.17 | 2023 | Talicia, Movantik, Aemcolo |
| Merck Sharp & Dohme LLC | $67.79 | 2023-2024 | Dificid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $50.51 | 2021 | |
| Celgene Corporation | $37.53 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $32.68 | 2023 | Linzess |
| Qol Medical, LLC | $25.03 | 2024 | Sucraid |
| Janssen Biotech, INC. | $17.34 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $16.68 | 2023 | Sutab |
| Ardelyx, INC. | $13.18 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Lapasaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.